A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Fulvestrant Plus BPI-16350 or Plus Placebo in Patients With HR+, HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer With Disease Progression Following Endocrine Therapy
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Fulvestrant (Primary) ; Tibremciclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms Tiffany
- Sponsors Betta Pharmaceuticals Co Ltd
Most Recent Events
- 25 Jul 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Jun 2022 New trial record